Serine
- Generic Name
- Serine
- Brand Names
- Hepatamine 8, Clinimix 2.75/5, Clinimix E 2.75/5, Clinisol 15, Premasol, Procalamine 3, Plenamine, Primene, Periolimel, Freamine III 10, Trophamine 10 %, Aminosyn II 7 %, Aminosyn-PF 7%, Prosol, Sulfite-free, Travasol 10, Olimel, Freamine 6.9
- Drug Type
- Small Molecule
- Chemical Formula
- C3H7NO3
- CAS Number
- 56-45-1
- Unique Ingredient Identifier
- 452VLY9402
- Background
A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from glycine or threonine. It is involved in the biosynthesis of purines; pyrimidines; and other amino acids.
- Indication
Used as a natural moisturizing agent in some cosmetics and skin care products.
- Associated Conditions
- Iron Deficiency Anemia (IDA), Iron Deficiency (ID)
- Associated Therapies
- Amino acid supplementation
Hereditary Sensory Neuropathy Serine Trial
- Conditions
- Hereditary Sensory Neuropathy Type I
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-11-02
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- University College, London
- Target Recruit Count
- 50
- Registration Number
- NCT06113055
- Locations
- 🇬🇧
University College London, London, United Kingdom
The Effect of Intradialytic Parenteral Nutrition on Nutritional Status and Quality of Life in Hemodialysis Patients
- Conditions
- End Stage Renal DiseaseMalnutritionSarcopeniaHemodialysis Complication
- Interventions
- Drug: Glucose IV
- First Posted Date
- 2019-09-18
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Erasmus Medical Center
- Target Recruit Count
- 166
- Registration Number
- NCT04094038
- Locations
- 🇳🇱
Erasmus MC, Rotterdam, Netherlands
🇳🇱Franciscus Gasthuis & Vlietland, Rotterdam, Netherlands
The Effect of Higher Protein Dosing in Critically Ill Patients: A Multicenter Randomized Trial
- Conditions
- FrailtySarcopeniaNutritional DisorderCritical IllnessMalnutrition
- Interventions
- First Posted Date
- 2019-07-09
- Last Posted Date
- 2022-10-27
- Lead Sponsor
- RWTH Aachen University
- Registration Number
- NCT04012333
- Locations
- 🇩🇪
University Hospital RWTH Aachen, Aachen, NRW, Germany
Reaching Protein Target With SmofKabiven® Extra Nitrogen vs Olimel N9E During the Early Phase of Acute Critical Illness
- Conditions
- Critical Illness
- Interventions
- First Posted Date
- 2019-06-20
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- Fresenius Kabi
- Target Recruit Count
- 7
- Registration Number
- NCT03992716
- Locations
- 🇫🇷
Hôpital Saint-Antoine, Département d'Anesthésie-Réanimation, Paris, France
🇩🇪Klinikum rechts der Isar, Klinik für Anaesthesiologie, München, Germany
🇵🇱SP ZOZ Wojewódzki Szpital Zespolony im. J. Śniadeckiego, Białystok, Poland
Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis (ALS)
- First Posted Date
- 2018-07-09
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Elijah W. Stommel
- Target Recruit Count
- 43
- Registration Number
- NCT03580616
- Locations
- 🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
Phase IIa L-serine Trial for eAD
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Aleksandra Stark
- Target Recruit Count
- 29
- Registration Number
- NCT03062449
- Locations
- 🇺🇸
Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States
Determining the Safety of L-serine in ALS
- First Posted Date
- 2013-04-19
- Last Posted Date
- 2015-07-30
- Lead Sponsor
- Phoenix Neurological Associates, LTD
- Target Recruit Count
- 20
- Registration Number
- NCT01835782
- Locations
- 🇺🇸
Phoenix Neurological Associates, Phoenix, Arizona, United States
🇺🇸Forbes Norris MDA/ALS Research Center, San Francisco, California, United States
L-Serine Supplementation in Hereditary Sensory Neuropathy Type 1
- Conditions
- Hereditary Sensory and Autonomic Neuropathy Type I
- Interventions
- Drug: placebo
- First Posted Date
- 2012-11-27
- Last Posted Date
- 2018-09-12
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 18
- Registration Number
- NCT01733407
- Locations
- 🇺🇸
UMass Medical Center, Worcester, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Trial of Supplemental Parenteral Nutrition in Under and Over Weight Critically Ill Patients (TOP-UP)
- Conditions
- Critical IllnessAcute Respiratory Failure
- Interventions
- First Posted Date
- 2010-09-21
- Last Posted Date
- 2021-03-16
- Lead Sponsor
- Clinical Evaluation Research Unit at Kingston General Hospital
- Target Recruit Count
- 125
- Registration Number
- NCT01206166
- Locations
- 🇺🇸
Mercy Hospital St. Louis, Saint Louis, Missouri, United States
🇺🇸The Ohio State Univsersity Medical Center, Columbus, Ohio, United States
🇺🇸Oregon Health & Science University, Portland, Oregon, United States
Gemcitabine With or Without WX-671 in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2007-07-11
- Last Posted Date
- 2012-03-29
- Lead Sponsor
- Heidelberg Pharma AG
- Target Recruit Count
- 95
- Registration Number
- NCT00499265
- Locations
- 🇭🇺
University of Pecs Faculty of Medicine, Pecs, Hungary
🇭🇺Debreceni Egyetem Onkologiai Tanzek, Debrecen, Hungary
🇭🇺Petz Aladar County Hospital, Gydr, Hungary
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.